$STE · STERIS plc

STERIS plc filed an 8-K disclosing that its subsidiary entered into a Purchase and Sale Agreement on October 11, 2026, to acquire all equity interests of Xodus Medical, Inc., a specialty surgical products business, for $2.1 billion in cash at closing, with up to $150 million in additional earnout consideration tied to 2028 performance targets. The acquisition will be financed primarily with debt, backed by a $2.0 billion senior unsecured bridge facility commitment from JPMorgan and Goldman Sachs. Closing is expected by December 31, 2026, subject to regulatory approvals and customary conditions

Markets closed — no regular-session reaction yet; extended-hours move not captured here. The $2.1B deal represents roughly 10% of STERIS's $21.22B market cap, a sizable but digestible transaction.

A $2.1 billion debt-funded acquisition in the current rate environment signals confidence in Xodus's specialty surgical portfolio and STERIS's ability to extract synergies, but adds meaningful

STERIS expands its specialty surgical products portfolio through this bolt-on acquisition, consistent with med-tech consolidation trends where scaled players acquire niche assets to broaden product lines and cross-sell into existing hospital networks.

Regulatory approvals may not be received, may be delayed, or may impose adverse conditions. Cost savings, tax benefits, and synergies from the acquisition may not materialize on the expected timeline or at all. The debt financing increases leverage and may limit financial flexibility.